Skip to content
Exploiting a Vulnerability in Cancers episode artwork

Jun 30, 2022 27 min

Exploiting a Vulnerability in Cancers

from The Bio Report Hosted by Levine Media Group

In cancer, synthetic lethality refers to a state in which two genetic mutations that alone may allow a cancer cell to survive will kill it when they exist simultaneously. Cyteir Therapeutics is seeking to exploit that strategy with what it calls next-generation synthetically lethal therapies to treat a wide range of cancers. We spoke to Markus Renschler, president and CEO of Cyteir therapeutics, about synthetic lethality, Cyteir’s pipeline, and life as a small public biotech in 2022.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Exploiting a Vulnerability in Cancers

0:00 27:54

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 27 minutes long.

When was this The Bio Report episode published?

This episode was published on June 30, 2022.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.